Trametinib + Anlotinib + Tislelizumab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Mutation-Related Tumors
Conditions
KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
Trial Timeline
Jul 1, 2024 → Dec 31, 2028
NCT ID
NCT06456138About Trametinib + Anlotinib + Tislelizumab
Trametinib + Anlotinib + Tislelizumab is a phase 1/2 stage product being developed by Novartis for KRAS Mutation-Related Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06456138. Target conditions include KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor.
What happened to similar drugs?
0 of 2 similar drugs in KRAS Mutation-Related Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06456138 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in KRAS Mutation-Related Tumors